A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged >= 65 Years.
Influenza, Human
Phase 3
An analysis-ready dataset is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013